Lindbrook Capital’s Arbutus Biopharma ABUS Stock Holding History

Lindbrook Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$991	Hold	284	–	–	﹤0.01%	2457
2024 Q4	$929	Hold	284	–	–	﹤0.01%	2496
2024 Q3	$1.09K	Hold	284	–	–	﹤0.01%	2483
2024 Q2	$878	Hold	284	–	–	﹤0.01%	2509
2024 Q1	$733	Hold	284	–	–	﹤0.01%	2469
2023 Q4	$710	Buy	+284	New	+$556	﹤0.01%	2534
2023 Q3	–	Sell	-833	Closed	-$1.75K	–	2685
2023 Q2	$1.92K	Hold	833	–	–	﹤0.01%	2160
2023 Q1	$2.52K	Hold	833	–	–	﹤0.01%	2147
2022 Q4	$1.94K	Buy	833 +639	+329%	+$1.53K	﹤0.01%	2238
2022 Q3	$0	Sell	194 -371	-66%	-$873	﹤0.01%	2595
2022 Q2	$2K	Buy	+565	New	+$1.45K	﹤0.01%	1890

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return

BCP

BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Lindbrook Capital's ABUS Position: Q1 2025 in Review

Lindbrook Capital held its Arbutus Biopharma (ABUS) position steady in Q1 2025 at 284 shares worth $991. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

Lindbrook Capital first reported a position in ABUS in Q2 2022 and has held it in 11 quarters since. The position peaked at $2.52K in Q1 2023. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

Lindbrook Capital held 284 shares of Arbutus Biopharma worth $991 as of Q1 2025.
Lindbrook Capital left its Arbutus Biopharma share count unchanged in Q1 2025.
Arbutus Biopharma made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2457 holding.
Lindbrook Capital first reported a position in Arbutus Biopharma in Q2 2022 and has held it in 11 quarters since.
Lindbrook Capital's Arbutus Biopharma position peaked at $2.52K in Q1 2023.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.